MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows:

• Biotech Showcase: The Investor Conference for Innovators will be held in-person in San Francisco from January 9-11, and virtually from January 18-19. The MAIA team will host investor meetings and is scheduled to present on Monday, January 9 at 4:00 pm PT. The webcast will be available on the News & Events page of the Investors section of the Company's website and the replay will be available for 60 days following the event.
• One-on-One Partnering at JPM in San Francisco from January 9-12. The management team will host meetings through BIO One-on-One Partnering at JPM.
• January 2023 Sidoti Micro-Cap Virtual Conference from January 18-19. The MAIA team will conduct investor meetings at this event.
• BIO CEO & Investor Conference will be held in-person in New York City from February 6-7 and virtually from February 8-9. The management team plans to conduct investor meetings and to present with the webcast available on the News & Events page of the Investors section of the Company's website.

Enrollment is underway in the Part A safety lead-arm of the THIO-101 Phase 2 clinical trial evaluating, THIO, an investigational telomere-targeting agent, in patients with advanced Non-Small Cell Lung Cancer (NSCLC). In the coming weeks, the Company expects to report data from the Part A arm.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with LIBTAYO^® (cemiplimab) an anti-PD1 therapy, developed and commercialized by Regeneron. For more information, please visit www.maiabiotech.com.

About MAIA Biotechnology, Inc.

MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.